Shares of Hims & Hers closed 5.1% higher after the company said it will expand its weight-loss offerings with branded ...

This is CNBC’s coverage of how U.S. trade partners, industries and employers respond to President Donald Trump’s historic tariffs.

April 2 (UPI) --Heart disease experts are hailing the results of a clinical trial that showed a strongly positive performance by Eli Lilly's drug lepodisiran, which inhibits the body's production ...

April 2 (Reuters) - Primary care company knownwell said on Wednesday it will provide health and weight-management services on Eli Lilly's (LLY.N), opens new tab direct-to-consumer online ...

Eli Lilly (NYSE:LLY) on Tuesday will file lawsuits against two companies that the drug giant is accusing of mass compounding its blockbuster GLP-1/GIP receptor agonist tirzepatide. Tirzepatide is ...

Lilly said in a statement that Zepbound can be prescribed by any licensed healthcare professional, adding that it has no affiliation with Hims & Hers. (Reporting by Sneha S K and Puyaan Singh in ...

Lilly said in a statement that Zepbound can be prescribed by any licensed healthcare professional, adding that it has no affiliation with Hims & Hers. (Reporting by Sneha S K and Puyaan Singh in ...